Company intelligence / Profile preview
Exponential Biotherapies, Inc.
New York, New York, United Statesexpobio.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
EBI’s lead product, a synthetic peptide derived from the human pregnancy hormone, has demonstrated positive results in Phase II clinical trials for reducing postoperative complications and is currently in Phase III studies. The therapy targets surgical stress and microvascular barrier dysfunction to reduce hospital length-of-stay and improve recovery. Additional indications are being explored for acute systemic inflammation and tissue injury post-radiation.
- Therapeutic areas
- OncologyImmunologyOtherNephrologyInfectious Diseases
- Modalities
- Synthetic peptides (polypeptides derived from human pregnancy hormone)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with Radboud University Medical Centre NijmegenScientific Advisory Board includes academic expertsNo major pharma partnerships disclosed publicly as of now.
Beyond the preview
Go deeper on Exponential Biotherapies, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exponential Biotherapies, Inc..